Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage

被引：44

作者：

Seiffge, David J. ^{[1
,2
,3
]}

Kagi, Georg ^{[4
]}

Michel, Patrik ^{[5
]}

Fischer, Urs ^{[6
]}

Bejot, Yannick ^{[7
]}

Wegener, Susanne ^{[8
]}

Zedde, Marialuisa ^{[9
]}

Turc, Guillaume ^{[10
]}

Cordonnier, Charlotte ^{[11
]}

Sandor, Peter S. ^{[12
]}

Rodier, Gilles ^{[13
]}

Zini, Andrea ^{[14
]}

Cappellari, Manuel ^{[15
]}

Schadelin, Sabine ^{[16
]}

Polymeris, Alexandros A. ^{[1
,2
,3
]}

Werring, David ^{[17
,18
]}

Thilemann, Sebastian ^{[1
,2
,3
]}

Maestrini, Ilaria ^{[11
]}

Berge, Eivind ^{[19
,20
]}

Traenka, Christopher ^{[1
,2
,3
]}

Vehoff, Jochen ^{[4
]}

De Marchis, Gian Marco ^{[1
,2
,3
]}

Kapauer, Monika ^{[4
]}

Peters, Nils ^{[1
,2
,3
,21
]}

Sirimarco, Gaia ^{[5
]}

Bonati, Leo H. ^{[1
,2
,3
]}

Arnold, Marcel ^{[6
]}

Lyrer, Philippe A. ^{[1
,2
,3
]}

De Maistre, Emmanuel ^{[22
]}

Luft, Andreas ^{[8
]}

Tsakiris, Dimtrios A. ^{[23
]}

Engelter, Stefan T. ^{[1
,2
,3
,21
]}

机构：

[1] Univ Hosp Basel, Stroke Ctr, Petersgraben 4, CH-4031 Basel, Switzerland

[2] Univ Basel, Petersgraben 4, CH-4031 Basel, Switzerland

[3] Univ Hosp, Dept Clin Res, Dept Neurol, Basel, Switzerland

[4] St Gallen Cantonal Hosp, Dept Neurol, St Gallen, Switzerland

[5] Univ Hosp, Dept Neurol, Lausanne, Switzerland

[6] Inselspital Bern, Dept Neurol, Bern, Switzerland

[7] Univ Hosp, Dept Neurol, Dijon Stroke Registry, Dijon, France

[8] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[9] New Santa Maria Hosp, Inst Hospitalizat & Sci Care, Neurol Unit, Stroke Unit, Reggio Emilia, Italy

[10] St Anne Hosp, Natl Inst Hlth & Med Res, Dept Neurol, U894, Paris, France

[11] Univ Lille, Lille Univ Hosp Ctr, Natl Inst Hlth & Med Res, U1171,Degenerat & Vasc Cognit Disorders,Dept Neur, Lille, France

[12] Baden Cantonal Hosp, Dept Neurol, Baden, Switzerland

[13] Annecy Genevois Hosp Ctr, Dept Neurol, Epagny Metz Tessy, France

[14] Modena Univ Hosp, SAgostino Estense Hosp, Dept Neurosci, Stroke Unit, Modena, Italy

[15] Integrated Univ Hosp, USD Stroke Unit, DAI Neurosci, Verona, Italy

[16] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland

[17] UCL, Dept Brain Repair & Rehabil, Ctr Stroke Res, Inst Neurol, London, England

[18] Natl Hosp Neurol & Neurosurg, London, England

[19] Oslo Univ Hosp, Dept Internal Med, Oslo, Norway

[20] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway

[21] Univ Basel, Univ Ctr Med Aging & Rehabil Basel, Felix Platter Hosp, Neurorehabil Unit, Basel, Switzerland

[22] Univ Hosp, Hematol Lab, Dijon, France

[23] Univ Hosp Basel, Diagnost Hematol, Basel, Switzerland

来源：

ANNALS OF NEUROLOGY | 2018年 / 83卷 / 03期

关键词：

HEALTH-CARE PROFESSIONALS; INTRAVENOUS THROMBOLYSIS; ORAL ANTICOAGULANTS; IV THROMBOLYSIS; FACTOR XA; MANAGEMENT; GUIDELINES; COMPLICATIONS; REVERSAL;

D O I：

10.1002/ana.25165

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

ObjectiveInformation about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. MethodsIn a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. ResultsAmong 241 patients (median age=80 years, interquartile range [IQR]=73-84; median time from onset to admission=2 hours, IQR=1-4.5 hours; median RivLev=89ng/ml, IQR=31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR=30-202) and ICH patients (102ng/ml, IQR=51-165; p=0.24). Trough RivLev((137ng/ml)) occurred in 126/190 (66.3%) AIS and 34/51 (66.7%) ICH patients. Among AIS patients, 108/190 (56.8%) had RivLev100ng/ml. In ICH patients, 33/51 (64.7%) had RivLev75ng/ml. RivLev was associated with rivaroxaban dosage, and inversely with renal function and time since last intake (each p<0.05). INR1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev100ng/ml. INR1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev75ng/ml. InterpretationRivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459

引用

页码：451 / 459

页数：9

共 50 条

[31] Diabetes Mellitus Predicts Symptomatic Intracerebral Hemorrhage Following Thrombectomy in Acute Ischemic Stroke
Montalvo, Mayra
Yakhkind, Aleksandra
Jayaraman, Mahesh
McTaggart, Ryan
Chang, Andrew
Akiki, Ronald
Mac Grory, Brian
Cutting, Shawna
Burton, Tina
Reznik, Michael
Thompson, Bradford
Wendell, Linda
Rao, Shyam
Potter, Nicholas
Mahta, Ali
Sheth, Kevin
Willey, Joshua
Khatri, Pooja
Furie, Karen
Yaghi, Shadi
NEUROLOGY, 2019, 92 (15)
[32] Glucose Control and Risk of Symptomatic Intracerebral Hemorrhage Following Thrombolysis for Acute Ischemic Stroke
Southerland, Andrew M.
Mayer, Stephan A.
Chiota-McCollum, Nicole A.
Bolte, Ashley C.
Pauls, Qi
Pettigrew, L. Creed
Bleck, Thomas P.
Conaway, Mark
Johnston, Karen C.
NEUROLOGY, 2024, 102 (09) : e209323
[33] Intracerebral Hemorrhage after Thrombolytic Therapy in Acute Ischemic Stroke Patients with Renal Dysfunction
Chao, Tzu-Hao
Lin, Ting-Chun
Shieh, Yao
Chang, Ting-Yu
Hung, Kuo Lun
Liu, Chi-Hung
Lee, Tsong Hai
Chang, Yeu Jhy
Lee, Jiann Der
Chang, Chien Hung
EUROPEAN NEUROLOGY, 2013, 70 (5-6) : 316 - 321
[34] Microglial Responses after Ischemic Stroke and Intracerebral Hemorrhage
Taylor, Roslyn A.
Sansing, Lauren H.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013,
[35] Developmental Venous Anomaly Presenting with Spontaneous Intracerebral Hemorrhage, Acute Ischemic Stroke, and Seizure
Mullaguri, Naresh
Battineni, Anusha
Krishnaiah, Balaji
Migdady, Ibrahim
Newey, Christopher R.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (08)
[36] Intracerebral hemorrhage research, no longer the bridesmaid to ischemic stroke
Donnan, Geoffrey
INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (03) : 219 - 219
[37] Rates and Outcomes of Neurosurgical Treatment for Postthrombolytic Intracerebral Hemorrhage in Patients with Acute Ischemic Stroke
Siddiq, Farhan
Adil, Malik M.
Norby, Kiersten E.
Rahman, Haseeb A.
Qureshi, Adnan I.
WORLD NEUROSURGERY, 2014, 82 (05) : 678 - 683
[38] Diabetes Mellitus Predicts Symptomatic Intracerebral Hemorrhage Following Thrombectomy in Acute Ischemic Stroke
Montalvo, Mayra
Yakhind, Alexandra
Jayaraman, Mahesh
McTaggart, Ryan
Chang, Andrew
Akiki, Ronald
Mac Grory, Brain
Cutting, Shawna
Burton, Tina
Reznik, Michael
Thompson, Bradford
Wendell, Linda
Rao, Shyam
Potter, Stevenson
Sheth, Kevin N.
Willey, Joshua Z.
Furie, Karen
Khatri, Pooja
Yaghi, Shadi
STROKE, 2019, 50
[39] Hospital cost of ischemic stroke and intracerebral hemorrhage in Japanese stroke centers
Yoneda, Y
Okuda, S
Hamada, R
Toyota, A
Gotoh, J
Watanabe, M
Okada, Y
Ikeda, K
Ibayashi, S
Hasegawa, Y
HEALTH POLICY, 2005, 73 (02) : 202 - 211
[40] VA stroke (VASt) study: Intracerebral hemorrhage versus ischemic stroke
Goldstein, LB
Samsa, GP
Matchar, DB
Hoff-Lindquist, J
Horner, RD
ANNALS OF NEUROLOGY, 2004, 56 : S5 - S5

← 1 2 3 4 5 →